Global Deuterated Drugs Market
Global Deuterated Drugs Market

Deuterated Drugs Comprehensive Study by Type (Austedo, Zepsun, Others), Disease (Huntington’s disease, Tardive Dyskinesia, Cancer, Others) Players and Region - Global Market Outlook to 2027

Deuterated Drugs Market Segmented into XX Submarkets. | Forecast Years: 2022- 2027  

Jan 2022 Edition 207 Pages 92 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Deuterated Drugs?
A deuterated medicine is a small molecule pharmaceutical product in which one or more of the drug's hydrogen atoms have been replaced with the heavier stable isotope deuterium. Deuterated medications are broken down more slowly, linger in the body longer, and hence require less frequent doses. Deuterated pharmaceuticals have much lower rates of metabolism and thus a longer half-life due to the kinetic isotope effect.

The market study is broken down by Type (Austedo, Zepsun and Others) and major geographies with country level break-up.

The market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focusing towards the production technologies, efficiency enhancement and product life. There is various growth opportunity in this market which is captured by leading players via tracking the ongoing process enhancement and huge invest in market growth strategies. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Deuterated Drugs market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Alkeus Pharmaceuticals (United States), Camargo (United States), Celgene (United States), CombiPhos (United States), Concert Pharmaceuticals (United States), DeuteRx (United States), Enanta Pharmaceuticals (United States), Invent Pharmaceuticals (United States), Lundbeck A/S (Denmark) and Neuland Laboratories (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Otsuka Pharmaceuticals (Japan), PharmatrophiX (United States), Protia LLC (United States), Retrotope LLC (United States) and Teva ‎ (Israel).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Deuterated Drugs market by Type, Application and Region.

On the basis of geography, the market of Deuterated Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Disease, the sub-segment i.e. Huntington’s disease will boost the Deuterated Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

In 2021, Alkeus Launches Clinical Trial for Drug Designed to Reduce Toxins in Retina. The biotech company Alkeus is conducting a multi-center Phase II clinical trial for a drug (ALK-001) that targets the toxic build-up in the retina that is thought to cause degeneration and vision loss. The emerging therapy is a modified form of vitamin A, which when metabolized in the retina, results in much less waste. Scientists developed ALK-001 by replacing hydrogen atoms in vitamin A with deuterium. Known as deuterated vitamin A, it “burns cleaner” than the natural form. Deuterium is a safe, naturally occurring, stable form of hydrogen, which is present in the human body.


Market Trend
  • New and Innovative Product are Developing

Market Drivers
  • Extending Patent Life
  • Dosing Frequency & Patient Adherence

Opportunities
  • Growing Healthcare Expenditure

Restraints
  • High Cost of Drugs
  • Side Effects may cause Persons Death

Challenges
  • Fluctuations in Drugs Supply and Demand Share Due to Enforcement of Stringent Lockdown Measures


Key Target Audience
Deuterated Drug Manufacturers, Deuterated Drug Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Frequently Asked Questions (FAQ):

1. What all players are profiled in the study?
The standard version of the report profiles players such as Alkeus Pharmaceuticals (United States), Camargo (United States), Celgene (United States), CombiPhos (United States), Concert Pharmaceuticals (United States), DeuteRx (United States), Enanta Pharmaceuticals (United States), Invent Pharmaceuticals (United States), Lundbeck A/S (Denmark) and Neuland Laboratories (India) etc.

2. Can we have customized study for Deuterated Drugs Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

3. What would be the Market Size of Deuterated Drugs Market by 2027?
Analysts at AMA estimates Deuterated Drugs Market to reach USD Million by 2027.
Report Objectives / Segmentation Covered
By Type
  • Austedo
  • Zepsun
  • Others
By Disease
  • Huntington’s disease
  • Tardive Dyskinesia
  • Cancer
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Extending Patent Life
      • 3.2.2. Dosing Frequency & Patient Adherence
    • 3.3. Market Challenges
      • 3.3.1. Fluctuations in Drugs Supply and Demand Share Due to Enforcement of Stringent Lockdown Measures
    • 3.4. Market Trends
      • 3.4.1. New and Innovative Product are Developing
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Deuterated Drugs, by Type, Disease and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Deuterated Drugs (Value)
      • 5.2.1. Global Deuterated Drugs by: Type (Value)
        • 5.2.1.1. Austedo
        • 5.2.1.2. Zepsun
        • 5.2.1.3. Others
      • 5.2.2. Global Deuterated Drugs by: Disease (Value)
        • 5.2.2.1. Huntington’s disease
        • 5.2.2.2. Tardive Dyskinesia
        • 5.2.2.3. Cancer
        • 5.2.2.4. Others
      • 5.2.3. Global Deuterated Drugs Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Deuterated Drugs (Volume)
      • 5.3.1. Global Deuterated Drugs by: Type (Volume)
        • 5.3.1.1. Austedo
        • 5.3.1.2. Zepsun
        • 5.3.1.3. Others
      • 5.3.2. Global Deuterated Drugs by: Disease (Volume)
        • 5.3.2.1. Huntington’s disease
        • 5.3.2.2. Tardive Dyskinesia
        • 5.3.2.3. Cancer
        • 5.3.2.4. Others
      • 5.3.3. Global Deuterated Drugs Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Deuterated Drugs (Price)
      • 5.4.1. Global Deuterated Drugs by: Type (Price)
  • 6. Deuterated Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Alkeus Pharmaceuticals (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Camargo (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Celgene (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. CombiPhos (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Concert Pharmaceuticals (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. DeuteRx (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Enanta Pharmaceuticals (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Invent Pharmaceuticals (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Lundbeck A/S (Denmark)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Neuland Laboratories (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Deuterated Drugs Sale, by Type, Disease and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Deuterated Drugs (Value)
      • 7.2.1. Global Deuterated Drugs by: Type (Value)
        • 7.2.1.1. Austedo
        • 7.2.1.2. Zepsun
        • 7.2.1.3. Others
      • 7.2.2. Global Deuterated Drugs by: Disease (Value)
        • 7.2.2.1. Huntington’s disease
        • 7.2.2.2. Tardive Dyskinesia
        • 7.2.2.3. Cancer
        • 7.2.2.4. Others
      • 7.2.3. Global Deuterated Drugs Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Deuterated Drugs (Volume)
      • 7.3.1. Global Deuterated Drugs by: Type (Volume)
        • 7.3.1.1. Austedo
        • 7.3.1.2. Zepsun
        • 7.3.1.3. Others
      • 7.3.2. Global Deuterated Drugs by: Disease (Volume)
        • 7.3.2.1. Huntington’s disease
        • 7.3.2.2. Tardive Dyskinesia
        • 7.3.2.3. Cancer
        • 7.3.2.4. Others
      • 7.3.3. Global Deuterated Drugs Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Deuterated Drugs (Price)
      • 7.4.1. Global Deuterated Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Deuterated Drugs: by Type(USD Million)
  • Table 2. Deuterated Drugs Austedo , by Region USD Million (2016-2021)
  • Table 3. Deuterated Drugs Zepsun , by Region USD Million (2016-2021)
  • Table 4. Deuterated Drugs Others , by Region USD Million (2016-2021)
  • Table 5. Deuterated Drugs: by Disease(USD Million)
  • Table 6. Deuterated Drugs Huntington’s disease , by Region USD Million (2016-2021)
  • Table 7. Deuterated Drugs Tardive Dyskinesia , by Region USD Million (2016-2021)
  • Table 8. Deuterated Drugs Cancer , by Region USD Million (2016-2021)
  • Table 9. Deuterated Drugs Others , by Region USD Million (2016-2021)
  • Table 10. South America Deuterated Drugs, by Country USD Million (2016-2021)
  • Table 11. South America Deuterated Drugs, by Type USD Million (2016-2021)
  • Table 12. South America Deuterated Drugs, by Disease USD Million (2016-2021)
  • Table 13. Brazil Deuterated Drugs, by Type USD Million (2016-2021)
  • Table 14. Brazil Deuterated Drugs, by Disease USD Million (2016-2021)
  • Table 15. Argentina Deuterated Drugs, by Type USD Million (2016-2021)
  • Table 16. Argentina Deuterated Drugs, by Disease USD Million (2016-2021)
  • Table 17. Rest of South America Deuterated Drugs, by Type USD Million (2016-2021)
  • Table 18. Rest of South America Deuterated Drugs, by Disease USD Million (2016-2021)
  • Table 19. Asia Pacific Deuterated Drugs, by Country USD Million (2016-2021)
  • Table 20. Asia Pacific Deuterated Drugs, by Type USD Million (2016-2021)
  • Table 21. Asia Pacific Deuterated Drugs, by Disease USD Million (2016-2021)
  • Table 22. China Deuterated Drugs, by Type USD Million (2016-2021)
  • Table 23. China Deuterated Drugs, by Disease USD Million (2016-2021)
  • Table 24. Japan Deuterated Drugs, by Type USD Million (2016-2021)
  • Table 25. Japan Deuterated Drugs, by Disease USD Million (2016-2021)
  • Table 26. India Deuterated Drugs, by Type USD Million (2016-2021)
  • Table 27. India Deuterated Drugs, by Disease USD Million (2016-2021)
  • Table 28. South Korea Deuterated Drugs, by Type USD Million (2016-2021)
  • Table 29. South Korea Deuterated Drugs, by Disease USD Million (2016-2021)
  • Table 30. Taiwan Deuterated Drugs, by Type USD Million (2016-2021)
  • Table 31. Taiwan Deuterated Drugs, by Disease USD Million (2016-2021)
  • Table 32. Australia Deuterated Drugs, by Type USD Million (2016-2021)
  • Table 33. Australia Deuterated Drugs, by Disease USD Million (2016-2021)
  • Table 34. Rest of Asia-Pacific Deuterated Drugs, by Type USD Million (2016-2021)
  • Table 35. Rest of Asia-Pacific Deuterated Drugs, by Disease USD Million (2016-2021)
  • Table 36. Europe Deuterated Drugs, by Country USD Million (2016-2021)
  • Table 37. Europe Deuterated Drugs, by Type USD Million (2016-2021)
  • Table 38. Europe Deuterated Drugs, by Disease USD Million (2016-2021)
  • Table 39. Germany Deuterated Drugs, by Type USD Million (2016-2021)
  • Table 40. Germany Deuterated Drugs, by Disease USD Million (2016-2021)
  • Table 41. France Deuterated Drugs, by Type USD Million (2016-2021)
  • Table 42. France Deuterated Drugs, by Disease USD Million (2016-2021)
  • Table 43. Italy Deuterated Drugs, by Type USD Million (2016-2021)
  • Table 44. Italy Deuterated Drugs, by Disease USD Million (2016-2021)
  • Table 45. United Kingdom Deuterated Drugs, by Type USD Million (2016-2021)
  • Table 46. United Kingdom Deuterated Drugs, by Disease USD Million (2016-2021)
  • Table 47. Netherlands Deuterated Drugs, by Type USD Million (2016-2021)
  • Table 48. Netherlands Deuterated Drugs, by Disease USD Million (2016-2021)
  • Table 49. Rest of Europe Deuterated Drugs, by Type USD Million (2016-2021)
  • Table 50. Rest of Europe Deuterated Drugs, by Disease USD Million (2016-2021)
  • Table 51. MEA Deuterated Drugs, by Country USD Million (2016-2021)
  • Table 52. MEA Deuterated Drugs, by Type USD Million (2016-2021)
  • Table 53. MEA Deuterated Drugs, by Disease USD Million (2016-2021)
  • Table 54. Middle East Deuterated Drugs, by Type USD Million (2016-2021)
  • Table 55. Middle East Deuterated Drugs, by Disease USD Million (2016-2021)
  • Table 56. Africa Deuterated Drugs, by Type USD Million (2016-2021)
  • Table 57. Africa Deuterated Drugs, by Disease USD Million (2016-2021)
  • Table 58. North America Deuterated Drugs, by Country USD Million (2016-2021)
  • Table 59. North America Deuterated Drugs, by Type USD Million (2016-2021)
  • Table 60. North America Deuterated Drugs, by Disease USD Million (2016-2021)
  • Table 61. United States Deuterated Drugs, by Type USD Million (2016-2021)
  • Table 62. United States Deuterated Drugs, by Disease USD Million (2016-2021)
  • Table 63. Canada Deuterated Drugs, by Type USD Million (2016-2021)
  • Table 64. Canada Deuterated Drugs, by Disease USD Million (2016-2021)
  • Table 65. Mexico Deuterated Drugs, by Type USD Million (2016-2021)
  • Table 66. Mexico Deuterated Drugs, by Disease USD Million (2016-2021)
  • Table 67. Deuterated Drugs Sales: by Type(K Units)
  • Table 68. Deuterated Drugs Sales Austedo , by Region K Units (2016-2021)
  • Table 69. Deuterated Drugs Sales Zepsun , by Region K Units (2016-2021)
  • Table 70. Deuterated Drugs Sales Others , by Region K Units (2016-2021)
  • Table 71. Deuterated Drugs Sales: by Disease(K Units)
  • Table 72. Deuterated Drugs Sales Huntington’s disease , by Region K Units (2016-2021)
  • Table 73. Deuterated Drugs Sales Tardive Dyskinesia , by Region K Units (2016-2021)
  • Table 74. Deuterated Drugs Sales Cancer , by Region K Units (2016-2021)
  • Table 75. Deuterated Drugs Sales Others , by Region K Units (2016-2021)
  • Table 76. South America Deuterated Drugs Sales, by Country K Units (2016-2021)
  • Table 77. South America Deuterated Drugs Sales, by Type K Units (2016-2021)
  • Table 78. South America Deuterated Drugs Sales, by Disease K Units (2016-2021)
  • Table 79. Brazil Deuterated Drugs Sales, by Type K Units (2016-2021)
  • Table 80. Brazil Deuterated Drugs Sales, by Disease K Units (2016-2021)
  • Table 81. Argentina Deuterated Drugs Sales, by Type K Units (2016-2021)
  • Table 82. Argentina Deuterated Drugs Sales, by Disease K Units (2016-2021)
  • Table 83. Rest of South America Deuterated Drugs Sales, by Type K Units (2016-2021)
  • Table 84. Rest of South America Deuterated Drugs Sales, by Disease K Units (2016-2021)
  • Table 85. Asia Pacific Deuterated Drugs Sales, by Country K Units (2016-2021)
  • Table 86. Asia Pacific Deuterated Drugs Sales, by Type K Units (2016-2021)
  • Table 87. Asia Pacific Deuterated Drugs Sales, by Disease K Units (2016-2021)
  • Table 88. China Deuterated Drugs Sales, by Type K Units (2016-2021)
  • Table 89. China Deuterated Drugs Sales, by Disease K Units (2016-2021)
  • Table 90. Japan Deuterated Drugs Sales, by Type K Units (2016-2021)
  • Table 91. Japan Deuterated Drugs Sales, by Disease K Units (2016-2021)
  • Table 92. India Deuterated Drugs Sales, by Type K Units (2016-2021)
  • Table 93. India Deuterated Drugs Sales, by Disease K Units (2016-2021)
  • Table 94. South Korea Deuterated Drugs Sales, by Type K Units (2016-2021)
  • Table 95. South Korea Deuterated Drugs Sales, by Disease K Units (2016-2021)
  • Table 96. Taiwan Deuterated Drugs Sales, by Type K Units (2016-2021)
  • Table 97. Taiwan Deuterated Drugs Sales, by Disease K Units (2016-2021)
  • Table 98. Australia Deuterated Drugs Sales, by Type K Units (2016-2021)
  • Table 99. Australia Deuterated Drugs Sales, by Disease K Units (2016-2021)
  • Table 100. Rest of Asia-Pacific Deuterated Drugs Sales, by Type K Units (2016-2021)
  • Table 101. Rest of Asia-Pacific Deuterated Drugs Sales, by Disease K Units (2016-2021)
  • Table 102. Europe Deuterated Drugs Sales, by Country K Units (2016-2021)
  • Table 103. Europe Deuterated Drugs Sales, by Type K Units (2016-2021)
  • Table 104. Europe Deuterated Drugs Sales, by Disease K Units (2016-2021)
  • Table 105. Germany Deuterated Drugs Sales, by Type K Units (2016-2021)
  • Table 106. Germany Deuterated Drugs Sales, by Disease K Units (2016-2021)
  • Table 107. France Deuterated Drugs Sales, by Type K Units (2016-2021)
  • Table 108. France Deuterated Drugs Sales, by Disease K Units (2016-2021)
  • Table 109. Italy Deuterated Drugs Sales, by Type K Units (2016-2021)
  • Table 110. Italy Deuterated Drugs Sales, by Disease K Units (2016-2021)
  • Table 111. United Kingdom Deuterated Drugs Sales, by Type K Units (2016-2021)
  • Table 112. United Kingdom Deuterated Drugs Sales, by Disease K Units (2016-2021)
  • Table 113. Netherlands Deuterated Drugs Sales, by Type K Units (2016-2021)
  • Table 114. Netherlands Deuterated Drugs Sales, by Disease K Units (2016-2021)
  • Table 115. Rest of Europe Deuterated Drugs Sales, by Type K Units (2016-2021)
  • Table 116. Rest of Europe Deuterated Drugs Sales, by Disease K Units (2016-2021)
  • Table 117. MEA Deuterated Drugs Sales, by Country K Units (2016-2021)
  • Table 118. MEA Deuterated Drugs Sales, by Type K Units (2016-2021)
  • Table 119. MEA Deuterated Drugs Sales, by Disease K Units (2016-2021)
  • Table 120. Middle East Deuterated Drugs Sales, by Type K Units (2016-2021)
  • Table 121. Middle East Deuterated Drugs Sales, by Disease K Units (2016-2021)
  • Table 122. Africa Deuterated Drugs Sales, by Type K Units (2016-2021)
  • Table 123. Africa Deuterated Drugs Sales, by Disease K Units (2016-2021)
  • Table 124. North America Deuterated Drugs Sales, by Country K Units (2016-2021)
  • Table 125. North America Deuterated Drugs Sales, by Type K Units (2016-2021)
  • Table 126. North America Deuterated Drugs Sales, by Disease K Units (2016-2021)
  • Table 127. United States Deuterated Drugs Sales, by Type K Units (2016-2021)
  • Table 128. United States Deuterated Drugs Sales, by Disease K Units (2016-2021)
  • Table 129. Canada Deuterated Drugs Sales, by Type K Units (2016-2021)
  • Table 130. Canada Deuterated Drugs Sales, by Disease K Units (2016-2021)
  • Table 131. Mexico Deuterated Drugs Sales, by Type K Units (2016-2021)
  • Table 132. Mexico Deuterated Drugs Sales, by Disease K Units (2016-2021)
  • Table 133. Deuterated Drugs: by Type(USD/Units)
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Deuterated Drugs: by Type(USD Million)
  • Table 145. Deuterated Drugs Austedo , by Region USD Million (2022-2027)
  • Table 146. Deuterated Drugs Zepsun , by Region USD Million (2022-2027)
  • Table 147. Deuterated Drugs Others , by Region USD Million (2022-2027)
  • Table 148. Deuterated Drugs: by Disease(USD Million)
  • Table 149. Deuterated Drugs Huntington’s disease , by Region USD Million (2022-2027)
  • Table 150. Deuterated Drugs Tardive Dyskinesia , by Region USD Million (2022-2027)
  • Table 151. Deuterated Drugs Cancer , by Region USD Million (2022-2027)
  • Table 152. Deuterated Drugs Others , by Region USD Million (2022-2027)
  • Table 153. South America Deuterated Drugs, by Country USD Million (2022-2027)
  • Table 154. South America Deuterated Drugs, by Type USD Million (2022-2027)
  • Table 155. South America Deuterated Drugs, by Disease USD Million (2022-2027)
  • Table 156. Brazil Deuterated Drugs, by Type USD Million (2022-2027)
  • Table 157. Brazil Deuterated Drugs, by Disease USD Million (2022-2027)
  • Table 158. Argentina Deuterated Drugs, by Type USD Million (2022-2027)
  • Table 159. Argentina Deuterated Drugs, by Disease USD Million (2022-2027)
  • Table 160. Rest of South America Deuterated Drugs, by Type USD Million (2022-2027)
  • Table 161. Rest of South America Deuterated Drugs, by Disease USD Million (2022-2027)
  • Table 162. Asia Pacific Deuterated Drugs, by Country USD Million (2022-2027)
  • Table 163. Asia Pacific Deuterated Drugs, by Type USD Million (2022-2027)
  • Table 164. Asia Pacific Deuterated Drugs, by Disease USD Million (2022-2027)
  • Table 165. China Deuterated Drugs, by Type USD Million (2022-2027)
  • Table 166. China Deuterated Drugs, by Disease USD Million (2022-2027)
  • Table 167. Japan Deuterated Drugs, by Type USD Million (2022-2027)
  • Table 168. Japan Deuterated Drugs, by Disease USD Million (2022-2027)
  • Table 169. India Deuterated Drugs, by Type USD Million (2022-2027)
  • Table 170. India Deuterated Drugs, by Disease USD Million (2022-2027)
  • Table 171. South Korea Deuterated Drugs, by Type USD Million (2022-2027)
  • Table 172. South Korea Deuterated Drugs, by Disease USD Million (2022-2027)
  • Table 173. Taiwan Deuterated Drugs, by Type USD Million (2022-2027)
  • Table 174. Taiwan Deuterated Drugs, by Disease USD Million (2022-2027)
  • Table 175. Australia Deuterated Drugs, by Type USD Million (2022-2027)
  • Table 176. Australia Deuterated Drugs, by Disease USD Million (2022-2027)
  • Table 177. Rest of Asia-Pacific Deuterated Drugs, by Type USD Million (2022-2027)
  • Table 178. Rest of Asia-Pacific Deuterated Drugs, by Disease USD Million (2022-2027)
  • Table 179. Europe Deuterated Drugs, by Country USD Million (2022-2027)
  • Table 180. Europe Deuterated Drugs, by Type USD Million (2022-2027)
  • Table 181. Europe Deuterated Drugs, by Disease USD Million (2022-2027)
  • Table 182. Germany Deuterated Drugs, by Type USD Million (2022-2027)
  • Table 183. Germany Deuterated Drugs, by Disease USD Million (2022-2027)
  • Table 184. France Deuterated Drugs, by Type USD Million (2022-2027)
  • Table 185. France Deuterated Drugs, by Disease USD Million (2022-2027)
  • Table 186. Italy Deuterated Drugs, by Type USD Million (2022-2027)
  • Table 187. Italy Deuterated Drugs, by Disease USD Million (2022-2027)
  • Table 188. United Kingdom Deuterated Drugs, by Type USD Million (2022-2027)
  • Table 189. United Kingdom Deuterated Drugs, by Disease USD Million (2022-2027)
  • Table 190. Netherlands Deuterated Drugs, by Type USD Million (2022-2027)
  • Table 191. Netherlands Deuterated Drugs, by Disease USD Million (2022-2027)
  • Table 192. Rest of Europe Deuterated Drugs, by Type USD Million (2022-2027)
  • Table 193. Rest of Europe Deuterated Drugs, by Disease USD Million (2022-2027)
  • Table 194. MEA Deuterated Drugs, by Country USD Million (2022-2027)
  • Table 195. MEA Deuterated Drugs, by Type USD Million (2022-2027)
  • Table 196. MEA Deuterated Drugs, by Disease USD Million (2022-2027)
  • Table 197. Middle East Deuterated Drugs, by Type USD Million (2022-2027)
  • Table 198. Middle East Deuterated Drugs, by Disease USD Million (2022-2027)
  • Table 199. Africa Deuterated Drugs, by Type USD Million (2022-2027)
  • Table 200. Africa Deuterated Drugs, by Disease USD Million (2022-2027)
  • Table 201. North America Deuterated Drugs, by Country USD Million (2022-2027)
  • Table 202. North America Deuterated Drugs, by Type USD Million (2022-2027)
  • Table 203. North America Deuterated Drugs, by Disease USD Million (2022-2027)
  • Table 204. United States Deuterated Drugs, by Type USD Million (2022-2027)
  • Table 205. United States Deuterated Drugs, by Disease USD Million (2022-2027)
  • Table 206. Canada Deuterated Drugs, by Type USD Million (2022-2027)
  • Table 207. Canada Deuterated Drugs, by Disease USD Million (2022-2027)
  • Table 208. Mexico Deuterated Drugs, by Type USD Million (2022-2027)
  • Table 209. Mexico Deuterated Drugs, by Disease USD Million (2022-2027)
  • Table 210. Deuterated Drugs Sales: by Type(K Units)
  • Table 211. Deuterated Drugs Sales Austedo , by Region K Units (2022-2027)
  • Table 212. Deuterated Drugs Sales Zepsun , by Region K Units (2022-2027)
  • Table 213. Deuterated Drugs Sales Others , by Region K Units (2022-2027)
  • Table 214. Deuterated Drugs Sales: by Disease(K Units)
  • Table 215. Deuterated Drugs Sales Huntington’s disease , by Region K Units (2022-2027)
  • Table 216. Deuterated Drugs Sales Tardive Dyskinesia , by Region K Units (2022-2027)
  • Table 217. Deuterated Drugs Sales Cancer , by Region K Units (2022-2027)
  • Table 218. Deuterated Drugs Sales Others , by Region K Units (2022-2027)
  • Table 219. South America Deuterated Drugs Sales, by Country K Units (2022-2027)
  • Table 220. South America Deuterated Drugs Sales, by Type K Units (2022-2027)
  • Table 221. South America Deuterated Drugs Sales, by Disease K Units (2022-2027)
  • Table 222. Brazil Deuterated Drugs Sales, by Type K Units (2022-2027)
  • Table 223. Brazil Deuterated Drugs Sales, by Disease K Units (2022-2027)
  • Table 224. Argentina Deuterated Drugs Sales, by Type K Units (2022-2027)
  • Table 225. Argentina Deuterated Drugs Sales, by Disease K Units (2022-2027)
  • Table 226. Rest of South America Deuterated Drugs Sales, by Type K Units (2022-2027)
  • Table 227. Rest of South America Deuterated Drugs Sales, by Disease K Units (2022-2027)
  • Table 228. Asia Pacific Deuterated Drugs Sales, by Country K Units (2022-2027)
  • Table 229. Asia Pacific Deuterated Drugs Sales, by Type K Units (2022-2027)
  • Table 230. Asia Pacific Deuterated Drugs Sales, by Disease K Units (2022-2027)
  • Table 231. China Deuterated Drugs Sales, by Type K Units (2022-2027)
  • Table 232. China Deuterated Drugs Sales, by Disease K Units (2022-2027)
  • Table 233. Japan Deuterated Drugs Sales, by Type K Units (2022-2027)
  • Table 234. Japan Deuterated Drugs Sales, by Disease K Units (2022-2027)
  • Table 235. India Deuterated Drugs Sales, by Type K Units (2022-2027)
  • Table 236. India Deuterated Drugs Sales, by Disease K Units (2022-2027)
  • Table 237. South Korea Deuterated Drugs Sales, by Type K Units (2022-2027)
  • Table 238. South Korea Deuterated Drugs Sales, by Disease K Units (2022-2027)
  • Table 239. Taiwan Deuterated Drugs Sales, by Type K Units (2022-2027)
  • Table 240. Taiwan Deuterated Drugs Sales, by Disease K Units (2022-2027)
  • Table 241. Australia Deuterated Drugs Sales, by Type K Units (2022-2027)
  • Table 242. Australia Deuterated Drugs Sales, by Disease K Units (2022-2027)
  • Table 243. Rest of Asia-Pacific Deuterated Drugs Sales, by Type K Units (2022-2027)
  • Table 244. Rest of Asia-Pacific Deuterated Drugs Sales, by Disease K Units (2022-2027)
  • Table 245. Europe Deuterated Drugs Sales, by Country K Units (2022-2027)
  • Table 246. Europe Deuterated Drugs Sales, by Type K Units (2022-2027)
  • Table 247. Europe Deuterated Drugs Sales, by Disease K Units (2022-2027)
  • Table 248. Germany Deuterated Drugs Sales, by Type K Units (2022-2027)
  • Table 249. Germany Deuterated Drugs Sales, by Disease K Units (2022-2027)
  • Table 250. France Deuterated Drugs Sales, by Type K Units (2022-2027)
  • Table 251. France Deuterated Drugs Sales, by Disease K Units (2022-2027)
  • Table 252. Italy Deuterated Drugs Sales, by Type K Units (2022-2027)
  • Table 253. Italy Deuterated Drugs Sales, by Disease K Units (2022-2027)
  • Table 254. United Kingdom Deuterated Drugs Sales, by Type K Units (2022-2027)
  • Table 255. United Kingdom Deuterated Drugs Sales, by Disease K Units (2022-2027)
  • Table 256. Netherlands Deuterated Drugs Sales, by Type K Units (2022-2027)
  • Table 257. Netherlands Deuterated Drugs Sales, by Disease K Units (2022-2027)
  • Table 258. Rest of Europe Deuterated Drugs Sales, by Type K Units (2022-2027)
  • Table 259. Rest of Europe Deuterated Drugs Sales, by Disease K Units (2022-2027)
  • Table 260. MEA Deuterated Drugs Sales, by Country K Units (2022-2027)
  • Table 261. MEA Deuterated Drugs Sales, by Type K Units (2022-2027)
  • Table 262. MEA Deuterated Drugs Sales, by Disease K Units (2022-2027)
  • Table 263. Middle East Deuterated Drugs Sales, by Type K Units (2022-2027)
  • Table 264. Middle East Deuterated Drugs Sales, by Disease K Units (2022-2027)
  • Table 265. Africa Deuterated Drugs Sales, by Type K Units (2022-2027)
  • Table 266. Africa Deuterated Drugs Sales, by Disease K Units (2022-2027)
  • Table 267. North America Deuterated Drugs Sales, by Country K Units (2022-2027)
  • Table 268. North America Deuterated Drugs Sales, by Type K Units (2022-2027)
  • Table 269. North America Deuterated Drugs Sales, by Disease K Units (2022-2027)
  • Table 270. United States Deuterated Drugs Sales, by Type K Units (2022-2027)
  • Table 271. United States Deuterated Drugs Sales, by Disease K Units (2022-2027)
  • Table 272. Canada Deuterated Drugs Sales, by Type K Units (2022-2027)
  • Table 273. Canada Deuterated Drugs Sales, by Disease K Units (2022-2027)
  • Table 274. Mexico Deuterated Drugs Sales, by Type K Units (2022-2027)
  • Table 275. Mexico Deuterated Drugs Sales, by Disease K Units (2022-2027)
  • Table 276. Deuterated Drugs: by Type(USD/Units)
  • Table 277. Research Programs/Design for This Report
  • Table 278. Key Data Information from Secondary Sources
  • Table 279. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Deuterated Drugs: by Type USD Million (2016-2021)
  • Figure 5. Global Deuterated Drugs: by Disease USD Million (2016-2021)
  • Figure 6. South America Deuterated Drugs Share (%), by Country
  • Figure 7. Asia Pacific Deuterated Drugs Share (%), by Country
  • Figure 8. Europe Deuterated Drugs Share (%), by Country
  • Figure 9. MEA Deuterated Drugs Share (%), by Country
  • Figure 10. North America Deuterated Drugs Share (%), by Country
  • Figure 11. Global Deuterated Drugs: by Type K Units (2016-2021)
  • Figure 12. Global Deuterated Drugs: by Disease K Units (2016-2021)
  • Figure 13. South America Deuterated Drugs Share (%), by Country
  • Figure 14. Asia Pacific Deuterated Drugs Share (%), by Country
  • Figure 15. Europe Deuterated Drugs Share (%), by Country
  • Figure 16. MEA Deuterated Drugs Share (%), by Country
  • Figure 17. North America Deuterated Drugs Share (%), by Country
  • Figure 18. Global Deuterated Drugs: by Type USD/Units (2016-2021)
  • Figure 19. Global Deuterated Drugs share by Players 2021 (%)
  • Figure 20. Global Deuterated Drugs share by Players (Top 3) 2021(%)
  • Figure 21. Global Deuterated Drugs share by Players (Top 5) 2021(%)
  • Figure 22. BCG Matrix for key Companies
  • Figure 23. Alkeus Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 24. Alkeus Pharmaceuticals (United States) Revenue: by Geography 2021
  • Figure 25. Camargo (United States) Revenue, Net Income and Gross profit
  • Figure 26. Camargo (United States) Revenue: by Geography 2021
  • Figure 27. Celgene (United States) Revenue, Net Income and Gross profit
  • Figure 28. Celgene (United States) Revenue: by Geography 2021
  • Figure 29. CombiPhos (United States) Revenue, Net Income and Gross profit
  • Figure 30. CombiPhos (United States) Revenue: by Geography 2021
  • Figure 31. Concert Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 32. Concert Pharmaceuticals (United States) Revenue: by Geography 2021
  • Figure 33. DeuteRx (United States) Revenue, Net Income and Gross profit
  • Figure 34. DeuteRx (United States) Revenue: by Geography 2021
  • Figure 35. Enanta Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 36. Enanta Pharmaceuticals (United States) Revenue: by Geography 2021
  • Figure 37. Invent Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 38. Invent Pharmaceuticals (United States) Revenue: by Geography 2021
  • Figure 39. Lundbeck A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 40. Lundbeck A/S (Denmark) Revenue: by Geography 2021
  • Figure 41. Neuland Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 42. Neuland Laboratories (India) Revenue: by Geography 2021
  • Figure 43. Global Deuterated Drugs: by Type USD Million (2022-2027)
  • Figure 44. Global Deuterated Drugs: by Disease USD Million (2022-2027)
  • Figure 45. South America Deuterated Drugs Share (%), by Country
  • Figure 46. Asia Pacific Deuterated Drugs Share (%), by Country
  • Figure 47. Europe Deuterated Drugs Share (%), by Country
  • Figure 48. MEA Deuterated Drugs Share (%), by Country
  • Figure 49. North America Deuterated Drugs Share (%), by Country
  • Figure 50. Global Deuterated Drugs: by Type K Units (2022-2027)
  • Figure 51. Global Deuterated Drugs: by Disease K Units (2022-2027)
  • Figure 52. South America Deuterated Drugs Share (%), by Country
  • Figure 53. Asia Pacific Deuterated Drugs Share (%), by Country
  • Figure 54. Europe Deuterated Drugs Share (%), by Country
  • Figure 55. MEA Deuterated Drugs Share (%), by Country
  • Figure 56. North America Deuterated Drugs Share (%), by Country
  • Figure 57. Global Deuterated Drugs: by Type USD/Units (2022-2027)
Some of the key companies/manufacturers profiled in the report
  • Alkeus Pharmaceuticals (United States)
  • Camargo (United States)
  • Celgene (United States)
  • CombiPhos (United States)
  • Concert Pharmaceuticals (United States)
  • DeuteRx (United States)
  • Enanta Pharmaceuticals (United States)
  • Invent Pharmaceuticals (United States)
  • Lundbeck A/S (Denmark)
  • Neuland Laboratories (India)
Additional players considered in the study are as follows:
Otsuka Pharmaceuticals (Japan) , PharmatrophiX (United States) , Protia LLC (United States) , Retrotope LLC (United States) , Teva ‎ (Israel)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation